**Supplementary Table 1.**

Clinicopathological characteristics of molecular cervical cancer subgroups (TCGA)

|  |  |  |
| --- | --- | --- |
|  |  |  |
| **Variable** |  **Columnar (n=56) Squamous/Reserve (n=223)**No. of patients (%) | **Total (n=279)** | ***P*-value**a |
| Lymphovascular space invasion |  |  |  |  |
| AbsentPresent | 17 (53)15 (47) | 48 (46)56 (54) | 136 | 0.547 |
| Lymph node involvement |  |  |  |  |
| AbsentPresent | 28 (72)11 (28) | 93 (67)46 (33) | 178 | 0.698 |
| FIGO-stage |  |  |  |  |
| Early (I-IIA)Late (IIA1-IVB) | 41 (73)15 (27) | 124 (57)92 (43) | 272 | 0.033 |
| Grade |  |  |  |  |
| I-II (Well/Moderate)III (Poor) | 29 (57)22 (43) | 111 (56)87 (44) | 249 | 1.000 |
| HPV type |  |  |  |  |
| HPV16HPV18HPV45Other  | 28 (50)22 (39)6 (11)0 (0) | 139 (62)15 (7)17 (8)52 (23) | 279 | **<0.00001b** |
| Chemotherapy |  |  |  |  |
| Not receivedReceived | 22 (51)21 (49) | 83 (43)110 (57) | 236 | 0.397 |
| Radiotherapy |  |  |  |  |
| Not receivedReceived | 13 (29)32 (71) | 63 (32)132 (68) | 240 | 0.725 |

aBonferroni-adjustedα: 0.006. Statistically significant values are bold

b The ‘other HPV types’-group was excluded from analysis. The *P*-value stated is the result of the global Chi-square test. *P*-values of individual tests were compared to a Bonferroni-adjusted α. HPV18 was significantly enriched in the columnar-derived group (*χ*2 = 41.25, df =1, *P*<0.00001)